Tyrosinase activity, cellular melanin and visible skin colour are related but not interchangeable. A stronger evidence chain separates biochemical, tissue and optical endpoints before making an application decision.
Three endpoints cannot replace one another
Tyrosinase activity is a biochemical endpoint. Melanin amount, type and distribution are biological endpoints. Instrumental or observer-recorded skin colour is an optical endpoint. These levels can correlate, but cell viability, melanosome transfer, epidermal turnover, film formation and measurement geometry can break the link at each step.
A positive result at one level should therefore be treated as a mechanism signal. It should not automatically become a human brightening, photoprotection or finished-product conclusion.
Conflicting results are variables, not noise
The reviewed literature includes both promotion and inhibition of melanogenesis among compounds described under the same broad natural-product classes. Structure, glycosylation, model, exposure and endpoint may change the direction.
The practical response is to record the exact material, dose, model and endpoint rather than predict performance from labels such as natural or antioxidant.
A staged validation sequence
First confirm that a change in enzyme activity is not caused by assay interference or cytotoxicity. Then measure melanin amount, type and spatial distribution. Finally, test colour under controlled illumination, baseline skin tone and instrument geometry.
Only a direction that remains coherent across these levels should advance to formula-specific and human validation. Immediate optical effects from coverage, scattering or film formation must be separated from biological pigmentation change.
Evidence and use boundary
English-edited from the approved GreenDee Muzi science digest. The cited reviews support an evaluation framework, not a product efficacy, safety or market claim.